Abilify Maintena® is the brand name of a depot formulation of aripiprazole that has an FDA indication for the treatment of schizophrenia.
Important! If the person has not been on aripiprazole, oral aripiprazole should be used first. Only when you are sure that the person can tolerate aripiprazole should you consider transitioning to Abilify Maintena®.
When first starting on Abilify Maintena®, after the first injection, the patient should be continued on the previous oral antipsychotic for two weeks.
- Recommended starting and maintenance dose is 400 mg administered monthly as a single injection.
- Dose can be reduced to 300 mg in patients with adverse reactions
- Known CYP2D6 poor metabolizers: Recommended starting and maintenance dose is 300 mg administered monthly
Dosage forms available
Abilify Maintena® comes as a powder for reconstitution in two types of kits and in two strengths:
a) Single-dose pre-filled Dual Chamber Syringe (much more convenient), and
b) Single-dose vial (400-mg vial, 300-mg vial)
Two strengths are available: 300 mg and 400 mg
No refrigeration is required
How to inject
It must be given by intramuscular injection in the gluteus (buttocks)
When the time comes to actually administer Abilify Maintena, it is important to see the Product Information for details of how inject the medication:
Copyright 2015, Rajnish Mago, MD. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons, or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.